Limits...
ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques.

Lemperle G, Knapp TR, Sadick NS, Lemperle SM - Aesthetic Plast Surg (2009)

Bottom Line: No serious side effects have been reported to date according to the FDA's MAUDE reporting database.The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction.This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

View Article: PubMed Central - PubMed

Affiliation: Division of Plastic Surgery, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103, USA. glemperle@aol.com

ABSTRACT
After more than 25 years of research and development, in October 2006 ArteFill became the first and only permanent injectable wrinkle filler to receive FDA approval. ArteFill is a third-generation polymeric microsphere-based filler, following its predecessor Artecoll, which was marketed outside the United States between 1994 and 2006. ArteFill is approved for the correction of nasolabial folds and has been used in over 15,000 patients since its U.S. market introduction in February 2007. No serious side effects have been reported to date according to the FDA's MAUDE reporting database. ArteFill consists of polymethylmethacrylate (PMMA) microspheres (20% by volume), 30-50 microm in diameter, suspended in 3.5% bovine collagen solution (80% by volume) and 0.3% lidocaine. The collagen carrier is absorbed within 1 month after injection and completely replaced by the patient's own connective tissue within 3 months. Each cc of ArteFill contains approximately six million microspheres and histological studies have shown that long-term wrinkle correction consists of 80% of the patient's own connective tissue and 20% microspheres. The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction. This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

Show MeSH
The needle is placed correctly, one needle diameter deep in the dermal–subdermal junction
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2872009&req=5

Fig12: The needle is placed correctly, one needle diameter deep in the dermal–subdermal junction

Mentions: If the needle is in the correct plane, i.e., the junction of the dermis and subdermal fat, it will be possible to pull the dermis superficially causing a ridge or push the dermis deep causing a depression or groove (Fig. 12).Fig. 12


ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques.

Lemperle G, Knapp TR, Sadick NS, Lemperle SM - Aesthetic Plast Surg (2009)

The needle is placed correctly, one needle diameter deep in the dermal–subdermal junction
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2872009&req=5

Fig12: The needle is placed correctly, one needle diameter deep in the dermal–subdermal junction
Mentions: If the needle is in the correct plane, i.e., the junction of the dermis and subdermal fat, it will be possible to pull the dermis superficially causing a ridge or push the dermis deep causing a depression or groove (Fig. 12).Fig. 12

Bottom Line: No serious side effects have been reported to date according to the FDA's MAUDE reporting database.The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction.This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

View Article: PubMed Central - PubMed

Affiliation: Division of Plastic Surgery, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103, USA. glemperle@aol.com

ABSTRACT
After more than 25 years of research and development, in October 2006 ArteFill became the first and only permanent injectable wrinkle filler to receive FDA approval. ArteFill is a third-generation polymeric microsphere-based filler, following its predecessor Artecoll, which was marketed outside the United States between 1994 and 2006. ArteFill is approved for the correction of nasolabial folds and has been used in over 15,000 patients since its U.S. market introduction in February 2007. No serious side effects have been reported to date according to the FDA's MAUDE reporting database. ArteFill consists of polymethylmethacrylate (PMMA) microspheres (20% by volume), 30-50 microm in diameter, suspended in 3.5% bovine collagen solution (80% by volume) and 0.3% lidocaine. The collagen carrier is absorbed within 1 month after injection and completely replaced by the patient's own connective tissue within 3 months. Each cc of ArteFill contains approximately six million microspheres and histological studies have shown that long-term wrinkle correction consists of 80% of the patient's own connective tissue and 20% microspheres. The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction. This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

Show MeSH